Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Chemotherapy. Radiation. University of Erlangen, Erlangen, Germany

Survival: N/R
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Germany
City/State/Province: Erlangen
Hospital: University of Erlangen
Journal: Link
Date: 1/2007

Patients: This phase II trial involved 104 people with rectal adenocarcinoma. The median age was 61, ranging from 39 to 77 years. Seventy-three percent of the patients were men.

Treatment: Patients were given the chemotherapy drugs oxaliplatin and capecitabine before and after radiation and surgery.

Toxicity: Grade 5 toxic events (death) occurred in two patients; one due to septicemia and tumor progression, the other due to cardiac arrest. Diarrhea was the most common severe toxicity, 12% of patients had Grade 3 or 4 diarrhea. Other toxicities included leuokopenia, anemia, nausea/vomiting, dysuria, radiation dermatitis, and allergic reactions.

Results: The median survival time was not reported. Complete regression of the primary tumor was observed in 18 patients. A ‘pathological complete response’ was observed in 17 patients.

Support: Supported by grants from Hoffmann-La Roche and Sanofi-Aventis Pharma. Most of the authors have been a consultant, obtained research funds, and/or honoraria from them as well. Capecitabine is marketed by Hoffmann-La Roche as Xeloda, and oxaliplatin is marketed by Sanofi-Aventis as ELOXATIN (oxaliplatin injection).

Correspondence: Claus Rodel, M.D.

E-mail to a Friend Email Physician More Information